CURRENT STATUS OF PROBLEM OF EARLY DIAGNOSIS OF OVARIAN CANCER AND ITS SOLUTIONS (LITERATURE REVIEW)

Ovarian cancer (OC) is one of the most common malignant tumors of the reproductive system. The five-year survival rate is extremely low. This disease is difficult to verify due to lack of pathognomonic symptoms and timely diagnosis. The key issue to increase survival in ovarian cancer is finding new methods for early diagnosis. Thus, the development of new methods for diagnosis of ovarian cancer is one of the most urgent problems in modern oncology. The basic approach in this matter is searching for new biomarkers of ovarian cancer, which will be characterized by such concepts as sensitivity and specificity. Biomarkers present in modern oncology, including CA-125, have insufficient specificity and have low sensitivity. The advantage of using a combination of several diagnostic biomarkers instead of one or panels of markers has been proved. Modern proteomic technologies such as two-dimensional electrophoresis, mass spectrometric methods are a valuable tool for finding new biomarkers for various malignancies, particularly ovarian cancer. The best results are achieved by using SELDI-TOF technology (Surface-enhanced laser desorption/ionization time-of-flight), combining the use of chromatographic protein chips with mass spectrometric detection. Serum amyloid A1 deserves the greatest attention between all of the biomarkers identified using mass spectrometric methods, as its ability to have a direct influence on the development of the tumor has been proved. Also its increase by hundreds of times during the disease has been found compared to the other candidate biomarkers identified by mass spectrometry. The main characteristics of serum amyloid 1A have been analyzed and found as one of the most promising markers for the combined determination for prompt diagnosis of ovarian cancer.

1. Макаров О.В., Борисенко С.А. Профи- лактика, диагностика, лечение рака яични- ков. Российский медицинский журнал 1996;3:36–40. [Makarov O.V., Borisenko S.A. Prevention, diagnosis and treatment of ovarian cancer. Rossiyskiy meditsinskiy zhurnal = Russian Medical Journal 1996;3:36–40. (In Russ.)].

2. Аксель Е.М. Статистика злокачествен- ных новообразований женской половой сферы. Онкогинекология 2012;1:18–24. [Aksel E.M. Statistics of malignant neoplasms of female genitalia. Onkoginekologiya = Oncogynecology 2012;1:18–24. (In Russ.)].

3. Жорданиа К.И., Герштейн Е.С., Кушлинский Н.Е. и др. Опухоли яичников. Клиническая онкогинекология. Под ред. В.П. Козаченко. М.: Медицина, 2005. С. 220–69. [Jordania K.I., Gerstein E.S., Kushlinsky N.E. et al. Ovarian tumors. Clinical oncogynecology. Under ed. of V.P. Kozachenko. Moscow: Medicine, 2005. Pp. 220–69. (In Russ.)].

4. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61(4):212–36.

5. Ueland F.R., Depriest P., Desimone C. et al. The accuracy of examination under anesthesia and transvaginal sonography in evaluating ovarian size. Gynecol Oncol 2005;99(2):400–3.

6. Adam B.L., Qu Y., Davis J.W. et al. Serum protein fingerprinting coupled with a pattern- matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62(13):3609–14.

7. Jacobs I.J., Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3(4):355–66.

8. Skates S.J., Horick N., Yu Y. et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004;22(20): 4059–66.

9. Jacobs I.J., Rivera H., Oram D.H., Bast R.C. Jr. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. Br J Obstet Gynaecol 1993;100(12): 1120–4.

10. Woolas R.P., Conaway M.R., Xu F. et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995;59(1):111–6.

11. Jijon H.B., Madsen K.L., Walker J.W. et al. Serum amyloid A activates NF-kappaB and proinflammatory gene expression in human and murine intestinal epithelial cells. Eur J Immunol 2005;35(3):718–26.

12. Brower S.T., Tartter P., Weiss S. et al. Breast cancer and family history: levels of lipid- associated sialic acid in plasma and absent family history of breast cancer in women who have breast tumors. Mt Sinai J Med 1995;62(6):419–21.

13. Xu F.J., Yu Y.H., Daly L. et al. OVX1 as a marker for early stage endometrial carcinoma. Cancer 1994;73(7):1855–8.

14. Nozawa S., Aoki D., Yajima M. et al. CA54/61 as a marker for epithelial ovarian cancer. Cancer Res 1992;52(5):1205–9.

15. Wamunyokoli F.W., Bonome T., Lee J.Y. et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res 2006;12(3 Pt 1):690–700.

16. Baranova A., Gowder S., Naouar S. et al. Expression profile of ovarian tumors: distinct signature of Sertoli-Leydig cell tumor. Int J Gynecol Cancer 2006;16(6):1963–72.

17. Skubitz A.P., Pambuccian S.E., Argenta P.A., Skubitz K.M. Differential gene expression identifies subgroups of ovarian carcinoma. Transl Res 2006;148(5):223–48.

18. Agarwal R., Kaye S.B. Expression profiling and individualisation of treatment for ovarian cancer. Curr Opin Pharmacol 2006;6(4): 345–9.

19. Le Page C., Ouellet V., Madore J. et al. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer 2006;118(7):1750–58.

20. Petricoin E.F., Ardekani A.M., Hitt B.A. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359(9306):572–7.

21. Xiao Z., Prieto D., Conrads T.P. et al. Proteomic patterns: their potential for disease diagnosis. Mol Cell Endocrinol 2005; 230(1–2):95–106.

22. Говорун В.М., Арчаков А.И. Биохимия 2002;67:1341–59. [Govorun V.M., Archakov A.I. Biokhimiya = Biochemistry 2002;67: 1341–59. (In Russ.)].

23. Craven R.A., Totty N., Harnden P. et al. Laser capture microdissection and two- dimensional polyacrylamide gelelectrophoresis: evaluation of tissue preparation and sample limitations. Am J Pathol 2002;160(3):815–22.

24. Wulfkuhle J.D., Liotta L.A., Petricoin E.F. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003;3(4):267–75.

25. Unlu M., Morgan M.E., Minden J.S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997;18(11):2071–7.

26. Zhou G., Li H., DeCamp D. et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer- specific protein markers. Mol Cell Proteomics 2002;1(2):117–24.

27. Mor G., Visintin I., Lai Y. et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005;102(21):7677–82.

28. Petricoin E. 3rd, Liotta L.A. Counterpoint: The vision for a new diagnostic paradigm. Clin Chem 2003;49(8):1276–8.

29. Kozak K.R., Amneus M.W., Pusey S.M. et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003;100(21):12343–8.

30. Rai A.J., Zhang Z., Rosenzweig J. et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002;126(12):1518–26.

31. Kozak K.R., Su F., Whitelegge J.P. еt аl. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5(17):4589–96.

32. Moshkovskii S.A., Serebryakova M.V., Kuteykin-Teplyakov K.B. et аl. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005;5(14):3790–7.

33. Zhang Z., Bast R.C. Jr., Yu Y. et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64(16);5882–90.

34. Petricoin E.F., Liotta L.A. SELDI-TOF- based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004;15(1):24–30.

35. Rodland K.D. Mass spectrometry and biomarker development. Dis Markers 2004;20(3):129–30.

36. Diamandis E.P. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49(8):1272–5.

37. White C.N., Zhang Z., Chan D.W. Quality control for SELDI analysis. Clin Chem Lab Med 2005;43(2):125–6.

38. Rau B., Steinbach G., Baumgart K. et al. Serum amyloid A versus C-reactive protein in acute pancreatitis: clinical value of an alternative acute-phase reactant. Crit Care Med 2000;28(3):736–42.

39. Uhlar C.M., Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999;265(2): 501–23.

40. Casl M.T., Surina B., Glojnaric-Spasic I. et al. Serum amyloid A protein in patients with acute myocardial infarction. Ann Clin Biochem 1995;32(Pt 2):196–200.

41. Casl M.T., Coen D., Simic D. Serum amyloid A protein in the prediction of postburn complications and fatal outcome in patients with severe burns. Eur J Clin Chem Clin Biochem 1996;34(1):31–5.

42. Larson M.A., Wei S.H., Weber A. et al. Induction of human mammary-associated serum amyloid A3 expression by prolactin or lipopolysaccharide. Biochem Biophys Res Commun 2003;301(4):1030–7.

43. Biran H., Friedman N., Neumann L. et al. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 1986;39(7):794–7.

44. Rosenthal C.J., Franklin E.C., Frangione B., Greenspan J. Isolation and partial characterization of SAA-an amyloid-related protein from human serum. J Immunol 1976;116(5):1415–8.

45. Kaneti J., Winikoff Y., Zimlichman S., Shainkin-Kestenbaum R. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol Res 1984;12(5): 239–41.

46. Glojnaric I., Casl M.T., Simic D., Lukac J. Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab Med 2001;39(2):129–33.

47. Chan D.C., Chen C.J., Chu H.C. et al. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 2007;14(1):84–93.

48. Havrilesky L.J., Sanders G.D., Kulasingam S. et al. Development of an ovarian cancer screening decision model that incorporates disease heterogeneity. Cancer 2011;117(3):545–53.

49. Gao W.M., Kuick R., Orchekowski R.P. et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005;5:110.

50. Engwegen J.Y., Mehra N., Haanen J.B. et al. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Invest 2007;87(2):161–72.

51. Cho W.C., Yip T.T., Yip C. et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004;10(1 Pt 1):43–52.

52. Liu D.H., Wang X.M., Zhang L.J. et al. Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci 2007;20(1):33–40.

53. Gutfeld O., Prus D., Ackerman Z. et al. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J Histochem Cytochem 2006;54(1):63–73.

54. Kovacevic A., Hammer A., Sundl M. et al. Expression of serum amyloid A transcripts in human trophoblast and fetal-derived trophoblast-like choriocarcinoma cells. FEBS Lett 2006;580:161–7.

55. Lee I.N., Chen C.H., Sheu J.C. et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 2006;6(9):2865–73.